Pregabalin in the management of partial epilepsy

Amir M ArainVanderbilt University Medical Center, Department of Neurology, Nashville, TN, USAAbstract: Pregabalin is a new antiepileptic medication that works by binding to alpha 2 delta subunit of the voltage-dependent calcium channels present in presynaptic neurons. Its pharmacokinetic advantages...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Amir M Arain
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2009
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/fea3d6eb97a9481dbbb038ab85845af5
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:fea3d6eb97a9481dbbb038ab85845af5
record_format	dspace
spelling	oai:doaj.org-article:fea3d6eb97a9481dbbb038ab85845af52021-12-02T00:21:46ZPregabalin in the management of partial epilepsy1176-63281178-2021https://doaj.org/article/fea3d6eb97a9481dbbb038ab85845af52009-07-01T00:00:00Zhttp://www.dovepress.com/pregabalin-in-the-management-of-partial-epilepsy-a3394https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Amir M ArainVanderbilt University Medical Center, Department of Neurology, Nashville, TN, USAAbstract: Pregabalin is a new antiepileptic medication that works by binding to alpha 2 delta subunit of the voltage-dependent calcium channels present in presynaptic neurons. Its pharmacokinetic advantages include rapid and almost complete absorption, lack of protein binding, linear kinetics, absence of enzyme induction, and absence of interactions with other drugs. Pregabalin was found effective as adjunctive therapy for refractory partial-onset seizures, with up to 51% responder at a dose of 600 mg/day. The lowest effective dose was 150 mg/day. Pregabalin is also approved for treatment of painful diabetic polyneuropathy, postherpetic neuralgia and pain with fibromyalgia. Studies also suggest a beneficial effect on sleep and generalized anxiety disorders. Its main adverse effects in randomized adjunctive trials in adults have been mild to moderate. Most common side effects were dizziness, ataxia, somnolence and diplopia. Weight gain was not prominent in pivotal pregabalin trials, but was more problematic in long-term postmarketing analyses in epilepsy patients. Pregabalin, with its potent antiseizure effect, favorable pharmacokinetic profile, and effectiveness in common co-morbidities is an important addition to the treatment of epilepsy.Keywords: epilepsy, seizures, pregabalin, pharmacology, antiepileptic drugs, tolerability Amir M ArainDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 407-413 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Amir M Arain Pregabalin in the management of partial epilepsy
description	Amir M ArainVanderbilt University Medical Center, Department of Neurology, Nashville, TN, USAAbstract: Pregabalin is a new antiepileptic medication that works by binding to alpha 2 delta subunit of the voltage-dependent calcium channels present in presynaptic neurons. Its pharmacokinetic advantages include rapid and almost complete absorption, lack of protein binding, linear kinetics, absence of enzyme induction, and absence of interactions with other drugs. Pregabalin was found effective as adjunctive therapy for refractory partial-onset seizures, with up to 51% responder at a dose of 600 mg/day. The lowest effective dose was 150 mg/day. Pregabalin is also approved for treatment of painful diabetic polyneuropathy, postherpetic neuralgia and pain with fibromyalgia. Studies also suggest a beneficial effect on sleep and generalized anxiety disorders. Its main adverse effects in randomized adjunctive trials in adults have been mild to moderate. Most common side effects were dizziness, ataxia, somnolence and diplopia. Weight gain was not prominent in pivotal pregabalin trials, but was more problematic in long-term postmarketing analyses in epilepsy patients. Pregabalin, with its potent antiseizure effect, favorable pharmacokinetic profile, and effectiveness in common co-morbidities is an important addition to the treatment of epilepsy.Keywords: epilepsy, seizures, pregabalin, pharmacology, antiepileptic drugs, tolerability
format	article
author	Amir M Arain
author_facet	Amir M Arain
author_sort	Amir M Arain
title	Pregabalin in the management of partial epilepsy
title_short	Pregabalin in the management of partial epilepsy
title_full	Pregabalin in the management of partial epilepsy
title_fullStr	Pregabalin in the management of partial epilepsy
title_full_unstemmed	Pregabalin in the management of partial epilepsy
title_sort	pregabalin in the management of partial epilepsy
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/fea3d6eb97a9481dbbb038ab85845af5
work_keys_str_mv	AT amirmarain pregabalininthemanagementofpartialepilepsy
_version_	1718403841582432256

Pregabalin in the management of partial epilepsy

Documents similaires